Get the Stockscreener App
1.8547
4.87%
-0.0953
Neumora Therapeutics Inc stock is traded at $1.8547, with a volume of 652.50K.
It is down -4.87% in the last 24 hours and down -28.10% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
See More
Previous Close:
$1.95
Open:
$1.94
24h Volume:
652.50K
Relative Volume:
0.23
Market Cap:
$315.04M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.7318
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
-3.89%
1M Performance:
-28.10%
6M Performance:
-84.27%
1Y Performance:
-89.07%
1-Day Range:
$1.83
$1.96
1-Week Range:
$1.81
$1.99
52-Week Range:
$1.81
$21.00
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.855 | 315.04M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.61 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
650.90 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.54 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) - GlobeNewswire Inc.
NMRA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Neumora Therapeutics, Inc. – NMRA - Business Wire
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Update - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Neumora Therapeutics and Other Stocks Suffer Major Losses as Market Faces Declines - HPBL
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $16.50 - Defense World
Neumora Stock Hits Record Low on Depression Drug Study Failure - MSN
Neumora Therapeutics, Inc. Presents Corporate Presentation at J.P. Morgan Healthcare Conference - Defense World
Neumora shares slump after depression drug fails in key trial - MSN
William Blair Reiterates Outperform Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
William Blair Reiterates "Outperform" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals - MSN
Neumora Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Barclays PLC Grows Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
3 US Penny Stocks With Market Caps Over $30M To Watch - Simply Wall St
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Bank of America Issues Pessimistic Forecast for Neumora Therapeutics (NASDAQ:NMRA) Stock Price - Defense World
Traders Purchase High Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Neumora Therapeutics's SWOT analysis: navacaprant setback tests resilience of CNS-focused biotech stock - Investing.com
Neumora’s Major Setback with Navacaprant Program: Industry Reacts - Zenopa
Stock Traders Buy Large Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora stock faces skepticism after failed trial, but BofA remains optimistic - Investing.com Canada
Bank of America Cuts Neumora Therapeutics (NASDAQ:NMRA) Price Target to $7.00 - MarketBeat
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
What is William Blair's Estimate for NMRA FY2029 Earnings? - MarketBeat
Stock in Biotech Neumora Plunges 80% as Depression Drug Fails - MSN
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neumora Therapeutics Inc Stock (NMRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fust Matthew K | Director |
Oct 17 '24 |
Option Exercise |
6.81 |
7,739 |
52,730 |
27,839 |
| Fust Matthew K | Director |
Oct 18 '24 |
Sale |
17.03 |
14,049 |
239,319 |
20,100 |
| Fust Matthew K | Director |
Oct 17 '24 |
Sale |
17.01 |
7,739 |
131,643 |
20,100 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):